Phase I clinical trials are designed to identify an appropriate dose for experimentation in phase II and III studies. I present the results from a simulation study to evaluate the performance of nine phase I designs involving the standard design, the two-stage modified Storer's design, the two-stage
Another look at two phase I clinical trial designs
โ Scribed by John O'Quigley
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 76 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
โฆ Synopsis
This note is a response to a recent paper by Korn et al. in which two phase I trial designs were compared, the designs in question being the standard design and the CRM design. The authors concluded that: (i) CRM designs will take longer to complete than standard designs; and (ii) CRM designs are less safe than the standard designs. These conclusions followed from a set of simulations for three di!erent dose toxicity situations. The "rst purpose of this note is to point out that these conclusions lean on false assumptions. The claims are in error. In their comparisons Korn et al. never in fact used CRM, as de"ned in O'Quigley, Pepe and Fisher, but a modi"ed version. The second purpose of this note is to look at the same cases studied by Korn et al. but this time using a correctly de"ned CRM model. Using the same comparison tools of Korn et al. we will see that for these situations, and indeed for a very wide class of other situations not presented here, not only are (i) and (ii) not true but that the exact opposite holds.
๐ SIMILAR VOLUMES